Ruth M McKernan

All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants.

Pharmacological Research October 1, 2025 Florian Freudenberg, Christine Reif-Leonhard, Gerard R Dawson et al.

Treatment-resistant depression (TRD) represents a major clinical challenge. Affecting about 30 % of major depressive disorder (MDD) patients, effective treatments for TRD are urgently needed. While depression research and antidepressant (AD) development have long centred on monoaminergic targets, research over the past 35 years has increasingly explored glutamatergic mechanisms. Here we present...